<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4309">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592705</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-1-092020</org_study_id>
    <nct_id>NCT04592705</nct_id>
  </id_info>
  <brief_title>Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients</brief_title>
  <official_title>Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larkin Community Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larkin Community Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the current lack of an effective drug or therapy, a clinical trial to better understand&#xD;
      the safety and efficacy of therapeutic plasma exchange (TPE) in COVID-19 patients is urgently&#xD;
      needed. The goal of this trial is to study the efficacy and safety of TPE therapy in subjects&#xD;
      with moderate to severe COVID-19 by determining the morbidity and mortality after TPE&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical status downgrade or discharge.</measure>
    <time_frame>60 days</time_frame>
    <description>Clinical improvement will be defined as a point reduction in subjects' clinical status on the 8-point WHO ordinal scale for clinical improvement or discharge from the hospital, whichever comes first.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Therapeutic plasma exchange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic plasma exchange</intervention_name>
    <description>TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.&#xD;
Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP.</description>
    <arm_group_label>Therapeutic plasma exchange</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with moderate-severe COVID-19 infection including early acute lung injury&#xD;
             (ALI)/early acute respiratory distress syndrome (ARDS)&#xD;
&#xD;
          2. Able to provide Informed Consent signed by the subject or by the subject's legal or&#xD;
             healthcare proxy.&#xD;
&#xD;
          3. Admitted to the participating facilities as listed above (Larkin South Miami Hospital,&#xD;
             Larkin Palm Springs Hospital).&#xD;
&#xD;
          4. Subjects between 18 and 69 years of age.&#xD;
&#xD;
          5. If female, subjects that have a negative result in a quantitative b-HCG blood test if&#xD;
             they are within reproductive age.&#xD;
&#xD;
          6. A positive COVID-19 test via nasopharyngeal swab RT-PCR.&#xD;
&#xD;
          7. Agree to not participate in another clinical trial during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under 18 years of age or older than 69 years of age.&#xD;
&#xD;
          2. Severe disease, defined as:&#xD;
&#xD;
             i. dyspnea ii. respiratory frequency ≥ 30/min iii. blood oxygen saturation ≤ 93% iv.&#xD;
             partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300, and/or&#xD;
             v. lung infiltrates &gt; 50% within 24 to 48 hours;&#xD;
&#xD;
          3. Life-threatening disease, defined as:&#xD;
&#xD;
             i. respiratory failure ii. septic shock, and/or iii. multiple organ dysfunction or&#xD;
             failure&#xD;
&#xD;
          4. Unable to provide informed consent or decline to consent.&#xD;
&#xD;
          5. Sequential Organ Failure Assessment (SOFA) score of 12 or above.&#xD;
&#xD;
          6. Hemodynamic instability, sepsis, or other conditions causing inability to tolerate&#xD;
             fluid shifts&#xD;
&#xD;
          7. Inability to tolerate central line placement&#xD;
&#xD;
          8. Allergy to FFP or albumin&#xD;
&#xD;
          9. Severe hypocalcemia&#xD;
&#xD;
         10. Patients with heparin allergies should not receive heparin as an anticoagulant during&#xD;
             plasmapheresis&#xD;
&#xD;
         11. Patients taking angiotensin-converting enzyme (ACE) inhibitors are advised to stop&#xD;
             taking the medication for at least 24 hours before starting plasmapheresis&#xD;
&#xD;
         12. Active or recent bleeding (unless controlled for &gt;48 hours).&#xD;
&#xD;
         13. Thrombocytopenia (≤25,000/L).&#xD;
&#xD;
         14. Advanced cirrhosis with a history of esophageal varices.&#xD;
&#xD;
         15. Chronic kidney disease requiring hemodialysis.&#xD;
&#xD;
         16. Active solid or non-solid malignancy or Lymphoma within the last 2 years.&#xD;
&#xD;
         17. Heart failure (NYHA class III or IV).&#xD;
&#xD;
         18. HIV infection (AIDS criteria), a history of immunodeficiency, or subject is currently&#xD;
             receiving immunosuppressive therapy.&#xD;
&#xD;
         19. Women of childbearing age who are pregnant or intend to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
         20. Known history of chromosomal or genetic abnormalities.&#xD;
&#xD;
         21. History of hypersensitivity or any kind of adverse reaction to blood products.&#xD;
&#xD;
         22. Contraindication to transfusion of blood products, or refusal due to&#xD;
             religious/personal reasons.&#xD;
&#xD;
         23. Any kind of drug or alcohol dependence that would interfere with adherence to the&#xD;
             study requirements.&#xD;
&#xD;
         24. Already part of this trial, recruited at a different hospital.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Talalaev, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larkin Community Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Talalaev, D.O.</last_name>
    <phone>305-284-7500</phone>
    <email>MTalalaev@larkinhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Larkin Community Hospital</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Talalaev, D.O.</last_name>
      <phone>305-284-7500</phone>
      <email>MTalalaev@larkinhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larkin Community Hospital</investigator_affiliation>
    <investigator_full_name>Michael Talalaev, M.D., D.O.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>therapeutic plasma exchange</keyword>
  <keyword>covid19</keyword>
  <keyword>coronavirus</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04592705/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

